{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:34:09Z","timestamp":1791297249022,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA-135594"],"award-info":[{"award-number":["R21 CA-135594"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA-119617S1"],"award-info":[{"award-number":["R01 CA-119617S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA-119617"],"award-info":[{"award-number":["R01 CA-119617"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.nano.2010.12.009","type":"journal-article","created":{"date-parts":[[2011,1,9]],"date-time":"2011-01-09T04:28:12Z","timestamp":1294547292000},"page":"435-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Pharmacokinetics and biodistribution of lonidamine\/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"Lara","family":"Milane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-feng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Amiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2010.12.009_bb0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/02841869209088904","article-title":"Mechanisms of multidrug resistance in cancer treatment","volume":"31","author":"Harris","year":"1992","journal-title":"Acta Oncol"},{"key":"10.1016\/j.nano.2010.12.009_bb0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/10245330310001638974","article-title":"Pharmacogenomics of MDR1\/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies","volume":"9","author":"Jamroziak","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.nano.2010.12.009_bb0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0889-8588(18)30095-9","article-title":"P-glycoprotein in adult solid tumors. Expression and prognostic significance","volume":"9","author":"Leighton","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.nano.2010.12.009_bb0020","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tredan","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nano.2010.12.009_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1349-7006.2003.tb01345.x","article-title":"Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal","volume":"94","author":"Tsuruo","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1016\/j.nano.2010.12.009_bb0030","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/0008-5472.CAN-06-2574","article-title":"Ability to acquire drug resistance arises early during the tumorigenesis process","volume":"67","author":"Yague","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2010.12.009_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.semdp.2008.08.001","article-title":"Targeted therapies in breast cancer","volume":"25","author":"Rojo","year":"2008","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.nano.2010.12.009_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1049\/iet-syb:20070073","article-title":"Stochastic simulations of ErbB homo and heterodimerisation: potential impacts of receptor conformational state and spatial segregation","volume":"2","author":"Hsieh","year":"2008","journal-title":"IET Syst Biol"},{"key":"10.1016\/j.nano.2010.12.009_bb0045","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11481-006-9032-4","article-title":"Nanotechnology: a focus on nanoparticles as a drug delivery system","volume":"1","author":"Kingsley","year":"2006","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.nano.2010.12.009_bb0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2008.04.013","article-title":"Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers","volume":"130","author":"Batrakova","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2010.12.009_bb0055","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0031-6997(24)01494-7","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nano.2010.12.009_bb0060","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1158\/1535-7163.MCT-06-0141","article-title":"Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery","volume":"5","author":"Sinha","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nano.2010.12.009_bb0065","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ctrv.2008.04.003","article-title":"Multi-functional nanocarriers to overcome tumor drug resistance","volume":"34","author":"Jabr-Milane","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.nano.2010.12.009_bb0070","article-title":"Development of EGFR-targeted polymer blend nanocarriers for paclitaxel\/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells","author":"Milane","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2010.12.009_bb0075","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1096\/fj.05-4058com","article-title":"Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.nano.2010.12.009_bb0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2008.07.012","article-title":"Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo","volume":"363","author":"Song","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2010.12.009_bb0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0378-5173(02)00483-0","article-title":"Biodegradable poly(\u025b-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen","volume":"249","author":"Chawla","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2010.12.009_bb0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijpharm.2004.12.010","article-title":"Poly(ethylene oxide)-modified poly(\u025b-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer","volume":"293","author":"Shenoy","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2010.12.009_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bmc.14","article-title":"Analysis of lonidamine in rat serum and testis by high performance liquid chromatography","volume":"15","author":"Grippa","year":"2001","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.nano.2010.12.009_bb0100","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/mp800240j","article-title":"Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells","volume":"6","author":"Ganta","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2010.12.009_bb0105","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:06:47Z","timestamp":1761548807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963411000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1549963411000025"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2010.12.009","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and biodistribution of lonidamine\/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2010.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}